| Kidney diseases

Continuous biomanufacturing is reducing the cost of goods of biopharmaceuticals. Achieving continuous manufacturing requires expertise in equipment design.

Download the highlights of Andrea Isby's presentation at Repligen's DSP Workshop in Estonia from May 23rd, 2024 to learn more.

Download the presentation

High-throughput screening methodologies have accelerated downstream development for monoclonal antibodies by enabling parallelized evaluation of chromatographic resins across a range of conditions. However, scientists must now interpret results in a meaningful and consistent way.

Learn how Just - Evotec Biologics' Downstream Data Browser automates visualization of high-throughput datasets, fits response surface statistical models, standardizes report results from a high-throughput screening method and facilitates comparison across molecules allowing the accelerated development of continuous biomanufacturing processes.

Read our poster to learn more

Chinook Therapeutics and Evotec joined forces for a patient-centric target identification supported by strong translational evidence to initiate drug discovery programs with a focus on tubular failed repair and cross-talk in the tubulointerstitial niche.

DOWNLOAD

The 12^th edition of our Drug Discovery Update (DDup) provides insights into exciting new developments in 3D cell models including microtissues, organoids and organ-on-a-chip technology.

In this edition, it covers:

an introduction to 3D cellular models
- the need for better models to improve translation from in vitro to in vivo
- the relevance of 3D cellular models to kidney disease modelling and drug induced toxicity prediction
an overview of Evotec's 3D in vitro platforms
- glomerulus-on-a-chip to study kidney disease
- kidney organoids to study polycystic kidney disease
- organ microtissues to predict drug-induced toxicity
interviews with experts Dr Christodoulos Xinaris, Dr Reiner Class, Dr Magali Ferro and Dr Stephanie Ryder

LEARN MORE

Learn more about Evotec's long term vision in Kidney Disease therapeutics including:

Molecular patient databases
Patient derived disease models
Molecular profiles turned biomarkers
Evotec's footprint in chronic kidney disease

DOWNLOAD

Science Pool

Achieving Continuous Manufacturing through Equipment Design

The Downstream Data Browser

Human Data-driven, Patient-centric and Omics-enabled Target Identification

3D Cell Models DDup #12

Metabolic and Kidney Disease Long Term Vision Fact Sheet

Inhibition of NF-kB Inducing Kinase in IFNα-accelerated Lupus Nephritis

Identifying Regulators of Kidney Fibrosis

Drug Discovery Insight: Evotec and Bayer Partner to Fight Kidney Diseases

Targeting the Podocyte to Treat Glomerular Kidney Disease

Kidney Diseases 2.0 DDup #7